Sofosbuvir

Paul A. Pham, Pharm.D., David L. Thomas, M.D., M.P.H., Janessa M. Smith, Pharm.D. BCPS

INDICATIONS

FDA

  • Treatment of HCV genotype 1, 2, 3 or 4 as a component of a combination antiviral treatment regimen
  • Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection

NON-FDA APPROVED USES

  • In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotype 5 and 6

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: April 6, 2017